



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

25 JUL 2006

Stephen A. Bent
Foley and Lardner, LLP
3000 K Street, NW
Suite 500
Washington, DC 20007

In re Application of	:	
JACKSON, et al.	:	
PCT No.: PCT/IB03/04177	:	DECISION ON RENEWED
Application No.: 10/522,777	:	
Int. Filing Date: 18 August 2003	:	PETITION UNDER
Priority Date: 16 August 2002	:	
Atty. Docket No.: 027524-0122	:	37 CFR 1.47(a)
For: INHIBITION OF PHSPHOINOSTIDE	:	
3-DINASE BETA	:	

This decision is in response to applicant's "Renewed Petition Under 37 C.F.R. 1.47(a)" filed 06 July 2006 in the United States Patent and Trademark Office (USPTO).

BACKGROUND

On 09 May 2006, applicant was mailed a decision dismissing applicant's petition under 37 CFR 1.47 to accept the application without the signature of joint inventor Vijaya Kenche. Applicant was afforded two months to file any request for reconsideration.

On 06 July 2006, applicant filed the present renewed petition.

DISCUSSION

As discussed in the decision mailed 09 May 2006, a petition under 37 CFR 1.47(a) must be accompanied by (1) the fee under 37 CFR 1.17(g), (2) factual proof that the missing joint inventor refuses to execute the application or cannot be reached after diligent effort, (3) a statement of the last known address of the missing inventor, and (4) an oath or declaration by each 37 CFR 1.47(a) applicant on his or her own behalf and on behalf of the non-signing joint inventor. Applicant previously satisfied items 1-3.

Applicant has presently filed executed declarations which comply with 37 CFR 1.497(a)-(b) satisfying the remaining item. Therefore, it is proper to grant applicant's renewed petition at this time.

CONCLUSION

For the reasons stated above, applicant's renewed petition under 37 CFR 1.47(b) is **GRANTED**.

The application has an international filing date of 18 August 2003 under 35 U.S.C. 363, and will be given a date of **06 July 2006** under 35 U.S.C. 371(c)(1), (c)(2) and (c)(4).

As provided in 37 CFR 1.47(c), a notice of the filing of this application will be forwarded to the non-signing inventors at their last known addresses of record. A notice of the filing of the application under 37 CFR 1.47(b) will be published in the Official Gazette.

This application is being returned to the DO/EO/US for processing in accordance with this decision. Specifically, the mailing of a Notification of Acceptance (Form PCT/DO/EO/903).



Derek A. Putonen
Attorney Advisor
Office of PCT Legal Administration
Tel: (571) 272-3294
Fax: (571) 273-0459



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

25 JUL 2006

Dr. Vijaya Kenche
9 Kings Close
Oakleigh East
Victoria 3166
AUSTRALIA

In re Application of
JACKSON, et al.
PCT No.: PCT/IB03/04177
Application No.: 10/522,777
Int. Filing Date: 18 August 2003
Priority Date: 16 August 2002
Atty. Docket No.: 027524-0122
For: INHIBITION OF PHSPHOINOSTIDE
3-DINASE BETA

Dear Dr. Kenche:

You are named as an inventor in the above identified United States patent application, filed under the provisions of 37 CFR 1.47(a) and 35 U.S.C. 116. Should a patent be granted, you will be designated as an inventor. As a named inventor, you are entitled to inspect any paper in the file wrapper of the application, order copies of all or any part thereof (at a prepaid cost per 37 CFR 1.19) or to make your position of record in the application. Alternately, you may arrange to do any of the preceding through a registered patent agent or attorney presenting written authorization from you. If you care to join in the application, the law firm of record (see below) would presumably assist you. Joining in the application would entail the filing of the appropriate oath or declaration by you pursuant to 37 CFR 1.63.

Derek A. Putonen
Attorney Advisor
Office of PCT Legal Administration
Tel: (571) 272-3294
Fax: (571) 273-0459

Stephen A. Bent
Foley and Lardner, LLP
3000 K Street, NW
Suite 500
Washington, DC 20007